Amid inspection and recall woes, Aurobindo to shut down NJ site in April
An India-based generic manufacturing giant that has had its fair share of run-ins with FDA inspectors will close a New Jersey site, and eliminate 99 jobs in April.
Aurobindo filed a notice with the Department of Labor stating that its Dayton site will lay off 99 employees on April 26. Those employees include 50 dispensing operators, six associate chemists and two packing mechanics.
Employees will be paid their regular wage through the 60-day notice period, until the April separation date, the notice said. Aurobindo did not respond to a request for comment by the time of publication.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
